Table 2.
Antihypertensive medication prescribed to hypertensive patients at baseline and at the end of the study
| Antihypertensive drug class | Control group (Baseline, n = 99) (End of study, n = 99)a | Intervention group (Baseline, n = 98) (End of study, n = 98)a | P value |
|---|---|---|---|
| Loop diuretics (%) | 18.2 | 11.2 | 0.168 |
| 18.2 | 12.2 | 0.247 | |
| Thiazide diuretics (%) | 59.6 | 64.3 | 0.498 |
| 63.6 | 67.3 | 0.584 | |
| Potassium-sparing diuretic (%) | 6.1 | 3.1 | 0.498 |
| 6.1 | 4.1 | 0.747 | |
| Renin inhibitor (%) | 3.0 | 2.0 | 1.000 |
| 3.0 | 4.1 | 0.721 | |
| ACE inhibitors (%) | 32.3 | 33.7 | 0.841 |
| 32.3 | 35.7 | 0.617 | |
| Angiotensin II receptor antagonists (%) | 47.5 | 64.3 | 0.018 |
| 52.5 | 64.3 | 0.094 | |
| Calcium channel blockers (%) | 35.4 | 45.9 | 0.131 |
| 42.4 | 44.9 | 0.729 | |
| Beta blockers (%) | 47.5 | 41.8 | 0.427 |
| 47.5 | 42.9 | 0.517 | |
| Central alpha-2 agonists (%) | 8.1 | 7.1 | 0.806 |
| 8.1 | 6.1 | 0.590 |
Bold means that there is a statistically significant difference (P value < 0.05)
aIncludes last medication prescribed before the final study visit (including to dropouts)